Uncategorized
Ocriplasmin Clinical Update
Pravin U. Dugel, MD, and Carl D. Regillo, MD, FACS, discuss the real-world use of intravitreal ocriplasmin injection (Jetrea, ThromboGenics, Inc.). Topics include optimizing treatment outcomes and real world experience, macular adverse events and lens findings, OCT changes, visual function adverse events and ongoing safety initiatives.